Treatment of proteasome inhibitor (PI)-refractory multiple myeloma (MM) is challenging, with response rates of only 15% to 35% being achieved with next-generation drugs such as pomalidomide, carfilzomib, and daratumumab, alone…
American Society of Hematology: Promising activity of nelfinavir-…